Business
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., February 25, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2025. Full year 2025 revenues rose to a record $3.18 billion, reflecting 11% growth over 2024.
About this update from United Therapeutics Corporation
[{"type":"text","content":"SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., February 25, 2026--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2025. Full year 2025 revenues rose to a record $3.18 billion, reflecting 11% growth over 2024.","length":345,"tagName":"p"},{"type":"text","content":""As we close out another remarkable year with record total revenue for the fourth year in a row, I extend my thanks to our Unitherians whose unwavering commitment to innovation and excellence fuels our mission," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "Looking ahead, our ADVANCE OUTCOMES and TETON-1 clinical programs are on the cusp of unveiling pivotal data that could unlock significant new treatment options for patients, launching a period of transformational growth for UT."","length":556,"tagName":"p"},{"type":"text","content":"Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, added, "This was an exceptional year for our commercial organization, highlighted by strong double‑digit revenue growth and disciplined execution by our teams. Tyvaso continued its impressive trajectory in a growing market where we are steadily increasing our share of voice. Looking ahead, we believe our commercial strength, differentiated therapies, and expanding market opportunities position us well to continue delivering durable double‑digit revenue growth."","length":556,"tagName":"p"},{"type":"text","content":"Fourth Quarter and Full Year 2025 Financial Results","length":51,"tagName":"p"},{"type":"text","content":"Key financial highlights include (in millions, except per share data):","length":70,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"1","rowspan":"1","style":"vertical-align:bottom;padding-left:0.0px;width:49%;","val":[]},{"colspan":"5","rowspan":"1","style":"vertical-align:bottom;border-bottom:solid black 1.0pt;padding-left:0.0px;","val":[{"type":"text","content":"Three Months Ended December 31,","length":32,"tagName":"p","attribs":{}}]},{"colspan":"1","rowspan":"1","style":"vertical-align:bottom;padding-left:0.0px;width:1%;","val":[]},{"colspan":"5","rowspan":"1","style":"vertical-align:bottom;border-b...